

FRIDAY 13 JUN

SATURDAY 14 JUN

SUNDAY 15 JUN

MONDAY 16 JUN



Onsite



Synoptic



Scientific

Industry

Share



Rooms	—	+	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30	12:00	12:30	13:00	13:30	14:00	14:30
Clyde Auditorium				SY1 - Clinical impact of Immune mechanisms driving asthma				PL1 - Innovations and Emerging Therapies in Food Allergy: Bridging Research and Clinical Practice						SY3 - Beyond the future - perspectives in the diagnosis and treatment of allergy and asthma		
Meeting Academy M2											EAACI-COURSE - EAACI Course on immunology up					
Lomond Auditorium				SY2 - Cofactor-dependent food-induced anaphylaxis				PL2 - Infections and the Development of Allergy: Unraveling the Connections						SY4 - Management of severe food allergy in children		
Hall 1				IWS1 - Managing venom allergy: what's new				PL3 - EAACI Highlight Plenary session Focus on Angioedema and Mast Cell Diseases						EAACI Special Session 1 - NAIS Forum 2025 : Updates in Anaphylaxis		
Innovation Hub				IH1 - AI in allergy and lung health: predicting the future, transforming diagnosis										ET 1 - EAACI Enlightening Talks- 1		
Meeting Academy M1				IWS2 - Management of delayed drug hypersensitivity reactions							SSS 2 - EAACI & APAPARI Joint Symposium : Emerging concepts in the management of food			Industry Session		
Forth				IWS3 - Omics										GBD 1 - Ground breaking discoveries 1		
Boisdale					SSS 1 - EAACI & JSA Joint Symposium : New Insights into the Mechanism and Treatment Strategies for								JMA 2 - Nano- and new technologies in diagnosing and treating allergies			
Alsh				JMA 1 - Inborn errors of immunity: Increasing awareness in clinical practice												
Carron 1		MTE1 - Clinical studies on allergen immunotherapy with inhaled			L-OASO1 - Aerobiology and Pollution						L-OASO3 - Clinical Immunology		OASO1 - Occupational Allergy: back to the future			
Carron 2		MTE2 - Tips and tricks for biological treatment of CRSwNP: setting			L-OASO2 - Dermatology						L-OASO4 - Allergy Diagnosis		OASO2 - Biologics in the combined airway			
Dochart 1		MTE3 - MTE3			L-FTO1 - Allergen Immunotherapy						L-FTO3 - Asthma		FTO2 - Anaphylaxis, new perspectives and treatments			
Dochart 2		MTE4 - MTE4			L-FTO2 - Food Allergy						FTO1 - Mastocytosis and mast cells diseases		FTO3 - Urticaria and Angioedema			
EAACI Global Stage											POC - Codex Alimentarius & Precautionary Allergen Labelling (PAL): A New Era for Food Safety and		P & C 1 - Is premedication useful to prevent non-IgE mediated immediate drug		P & C 2 - Timi in oral immunotherap Early vs. Late introduction	
Poster Area											TPS - Poster Session					
E-TPS Display Only Digital section	e-TPS Display Only Digital section															

Scientific				Industry												Share		
Rooms				8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30	12:00	12:30	13:00	13:30	14:00	14:30	
Clyde Auditorium				SY9 - Impact of natural disasters on respiratory and immune health				PL4 - Drug Allergy: Advances in Diagnosis, Management, and Prevention						SY11 - T2 inflammation in the upper airways: from bench to bedside				
Lomond Auditorium								PL5 - Microbiota and Immune Regulation: Insights from Gut to Lungs Across the Lifespan						SY12 - Food allergy: from prevention to prediction of therapeutic responses				
Hall 1				SY10 - Chronic spontaneous urticaria: latest clinical developments				PL6 - Highlights of EAACI Guidelines: Latest Developments and Clinical Applications				SSS 3 - EAACI & SLAAI Joint Symposium : Air pollution In Latin America		TSY3 - Autoimmunity in allergic diseases: implications for treatment				
Innovation Hub				IH3 - Nanotechnology in allergy: From diagnostics to precision therapies										ET 2 - EAACI Enlightening Talks - 2				
Meeting Academy M1				IWS6 - Innovations in Betalactam allergy diagnosis								Industry Session						
Forth														SY13 - Therapeutic options in indolent systemic mastocytosis: a roadmap				
Boisdale					Industry Session										SSS 4 - EAACI & ACAAI Joint Symposium : Unified Airway Disease			
Alsh				JMA4 - Year in review								Industry Session				Industry Session		
Carron 1	MTE5 - Allergen immunotherapy for allergic disease: Indications and				L-OAS05 - Asthma: from bench to bedside								L-OAS07 - Oral immunotherapy for Food Allergy		OAS07 - Insights in pediatric allergy: from bench to bedside			
Carron 2	MTE6 - Pathogenic mechanisms in the evolution of food allergy				L-OAS06 - Basic Immunology								L-OAS08 - Pediatrics		OAS08 - Phenotypes and mechanisms in asthmatic diseases			
Dochart 1	MTE7 - Diversity of regulatory B cells: Markers and functions				L-FT04 - Food Allergy from Diagnosis to Management								L-FT06 - Clinical Immunology		FT08 - Biological treatment in asthmatic diseases			
Dochart 2	MTE8 - Clinical Pathway on direct drug provocation testing				L-FT05 - Allergy Diagnosis								L-FT07 - ENT		FT09 - Allergen immunotherapy in clinical studies			
EAACI Global Stage														P & C 3 - Is remission an adequate therapeutic goal for severe asthma			P & C 4 - Should dupilumab be the standard first treatment choice for severe atopy	
Poster Area												TPS - Poster Session						

Scientific															Industry													Share	
Rooms				8:30	9:00	9:30	10:00	10:30	11:00	11:30	12:00	12:30	13:00	13:30	14:00	14:30	15:00												
Clyde Auditorium					SY19 - Atopic dermatitis; the other side of the mirror				PL7 - New horizons in the management of severe atopic dermatitis						SY22 - Crosstalk between lung structural cells and immune cells in airway inflammation and remodeling														
Lomond Auditorium					SY20 - Present and future of allergen immunotherapy				PL8 - One Health: Addressing Environmental Challenges in Allergy and Immunology						SY23 - Breakthroughs Biologicals in allergic diseases														
Hall 1					SY21 - Very early nutrition and allergy outcomes				PL9 - Highlights of EAACI Task Forces: Bridging Innovation and Clinical Practice				SSS 7 - EAACI & APAACI Joint Symposium : Recent Developments in Environmental Issues		TSY6 - Molecular mapping of asthma: Decoding airway remodelling for targeted interventions														
Innovation Hub					IH5 - Telemedicine								PiSO1 - A booster for our (interconnected) future		ET 3 - EAACI Enlightening Talks - 3														
Meeting Academy M1					IWS9 - How to manage asthma patients in the clinic										GBD2 - Ground breaking discoveries 2														
Forth					IWS10 - Management of hypersensitivity to chemotherapy										SSS 8 - EAACI & WAO Joint Symposium - Improved approaches in food allergy														
Boisdale					SSS 6 - EAACI & KAAACI Joint Symposium : New horizons toward controlling allergy and										JMA6 - JM Sister Societies Symposium														
Alsh					TSY 5 - The role of mucus in asthma and CRS severity							Industry Session																	
Carron 1					OAS13 - Diagnosis and management of Eosinophilic Esophagitis							L-OAS09 - Food Allergy			OAS15 - Outcomes in chronic rhinosinusitis and type 2 inflammation														
Carron 2					OAS14 - Natural history and treatment of food allergy							L-OAS10 - Drug Allergy			OAS16 - Efficacy and safety of allergen immunotherapy in clinical practice														
Dochart 1					FT14 - Allied health and primary care							L-FT08 - Dermatology			FT16 - Immunodeficiencies and autoimmunity														
Dochart 2					FT15 - The Heterogenicity of asthma							L-FT09 - Anaphylaxis			FT17 - Predictive value of allergy test														
EAACI Global Stage					JMA5 - JM-NAS Symposium : Early life exposure and allergy development										P & C 5 - Should we be concerned when starting allergen immunotherapy											P & C 6 - Sti challenge te			
Poster Area												TPS - Poster Session																	

FRIDAY 13 JUN

SATURDAY 14 JUN

SUNDAY 15 JUN

MONDAY 16 JUN



Onsite



Synoptic



Scientific

Share



Rooms	9:00	9:30	10:00	10:30	11:00	11:30	12:00	12:30	13:00	13:30	14:00	14:30	15:00	
Clyde Auditorium	PL10 - Precision Medicine in Airway Diseases: Biomarkers and Phenotyping			SY29 - War related exposures and asthma development				SY33 - Drug allergy during childhood			Closing Ceremony			
Lomond Auditorium	PL11 - Biologicals in Allergy and Asthma: Where Are We?			SY30 - Rare cases in paediatric allergy clinical practice				SY34 - Focus on exercise and asthma management						
Hall 1				SY31 - Early life Immuno modulation				SY35 - Updates in the clinical management of allergen immunotherapy						
Meeting Academy M1				SY32 - Periocular and ocular surface disorders: Beyond What Meets the Eye				SY36 - Communication with allergic patients in primary care						
Forth				IWS15 - Methodology of Allergen challenges for airway allergy				IWS18 - Innovations in angioedema diagnosis						
Boisdale				IWS16 - Time to redefine healthy eating?				IWS19 - Food Allergy in Clinical Practice						
Alsh				SY37 - Biomarkers for asthma and allergic diseases				TSY8 - Allergenic risk of novel foods						
Carron 1				OAS21 - Update on major food allergies				OAS23 - Predicting pediatric asthma and airway disease						
Carron 2				OAS22 - Clinical Management				OAS24 - Clinical aspects of chronic urticaria						
Dochart 1				FT22 - Chronic rhinosinusitis: from bedside to bench				FT24 - Aerobiology and Climate change: something is blowing in the wind						
Dochart 2				FT23 - News in hereditary angioedema management				FT25 - Pre-clinical modeling of allergic and asthmatic diseases						

Last updated
10.04.2025, 10:24